Compare CYTK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | ABVX |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 10.5B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | ABVX |
|---|---|---|
| Price | $63.42 | $114.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 12 |
| Target Price | $87.56 | ★ $128.42 |
| AVG Volume (30 Days) | ★ 1.7M | 711.6K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $302.66 | $0.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.31 | $4.77 |
| 52 Week High | $70.98 | $148.83 |
| Indicator | CYTK | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 47.37 |
| Support Level | $59.25 | $106.37 |
| Resistance Level | $65.93 | $131.27 |
| Average True Range (ATR) | 2.54 | 4.85 |
| MACD | -0.34 | -1.26 |
| Stochastic Oscillator | 42.07 | 38.42 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.